6/17/2025
Research Projects Engineering T cells to overcome suppressive signals in the tumor microenvironment Engineered T cell therapy can effectively kill ovarian cancer cells, but there are still tumor-driven hurdles that T cells…
6/17/2025
Genetically engineering T cells with a chimeric antigen receptor (CAR) allows for recognition and subsequent destruction of cancer cells. While this has been a revolutionary treatment for many patients with…
6/17/2025
The focus of our work is on the use of costimulatory pathways, particularly the CD70-CD27 TNF-superfamily members, to promote immunotherapeutic T cell responses against melanoma and other malignancies, and as…
6/17/2025
6/17/2025
Research in the Dolatshahi lab combines multiplex experimental measurements with computational methods (including statistical machine learning, network inference, information theory, signal processing and kinetic-dynamic modeling) to solve problems in the…
6/17/2025
The Dudley Lab, associated with the Department of Microbiology, Immunology and Cancer Biology (MIC), is focused on the tumor microenvironment and mechanisms of tumor neovascularization. We use transgenic tumor models,…
6/17/2025
The work of my laboratory over the last 40 years has been broadly concerned with the recognition of antigens by CD8 T cells. In the last 20 years, that work…
6/17/2025
OVERVIEW: How does the body recognize an infectious organism? During infection, how does it determine when to escalate inflammation for pathogen clearance versus dampen inflammation to prevent damage to self? What…
6/17/2025
Targeted therapy: by serendipity, we identified a novel oncogene, and found that multiple cancers are addicted to its activity. This oncogene addiction is evidenced in glioblastoma, pediatric sarcoma, and others.…
6/17/2025
Dr. Loughran's current research includes: current research includes: • R01 grant from the NIH’s National Cancer Institute to identify and characterize the LGL leukemia virus and understand how it might cause leukemia; •…
